Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy infants aged between 6 and 35 months~2. full-term birth with birth weight above 2,500 grams~3. Subject and parent/legal representative should be present at all scheduled visits and to obey all trial procedures~Exclusion Criteria:~1. Volunteers in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination~2. Volunteers allergic to ingredient of vaccine composition (can be checked from vaccination history), especially to egg~3. History of progressive or severe neurologic disorder~4. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain~5. Known or suspected impairment/alteration of immune function, for example receiving immunosuppressive therapy or receiving blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation~6. Asthma that is unstable or required emergent care, hospitalization or intubation during the past two years or that required the use of oral or intravenous corticosteroids~7. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws~8. History of thyroidectomy or thyroid disease that required medication within the past 12 months~9. Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years~10. Guillain-Barre Syndrome~11. Self-reported seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C~12. Any other vaccines or immunoglobulin preparation within 1 weeks prior to enrollment~13. Axillary temperature ≥ 38.0 degrees Celsius within 3 days of intended study vaccination~14. Any conditions may influence the evaluation

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 36 Months
- Healthy Volunteers: t

Study Arms:
- split-virion, non-adjuvanted vaccine of 7.5 μg (Type: EXPERIMENTAL): split-virion, non-adjuvanted H1N1 vaccine of 7.5 μg.
- split-virion, non-adjuvanted vaccine of 15 μg (Type: EXPERIMENTAL): split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
- split-virion, non-adjuvanted vaccine of seasonal influenza (Type: PLACEBO_COMPARATOR): split-virion, non-adjuvanted H1N1 vaccine of seasonal influenza.

Based on this trial design, predict the completion outcome and termination type (if applicable).